"We do not think the US FDA's inspection and clearance process for Ranbaxy's facilities would be influenced by inspections conducted by other regulatory authorities especially given that the issues in the September 2008 warning letter appear to relate primarily to the Batamandi unit. With the AIP being invoked and data generated from the plant under scrutiny, Ranbaxy will have to demonstrate that the issues that led to such data have been resolved—which could be a long, drawn-out process," said analyst Prashant Nair at Citi Investment Research and Analysis.